Page 4 - Pharma

Biocon Biologics gets licence from Adagio for antibody Covid treatment

Initial data indicate that ADG20 could provide both rapid and durable protection against Covid-19 for up to one year

Why switching over to laggards may prove rewarding in stock market

FMCG, Pharma and Energy are sectors that have delivered lower returns than benchmark indices in the past year

Hetero recalls a batch of its remdesivir brand Covifor after side effects

Some patients in Raigad district of Maharashtra developed side effects like fever and chills

Key Covid-19 bulk drugs see 180% price increase over four months

However, there is no shortage expected at the retail level anytime soon

Govt should have built safety stock of essential drugs: Kiran Mazumdar-Shaw

The Biocon founder and Executive Chairperson points out that drugs like Remdesivir should be allowed at home as an emergency step

Single dose of Pfizer vaccine cuts Covid-19 spread by half: Study

Protection against coronavirus seen from about 14 days after vaccination

25 new plants approved to enhance supply of Remdesivir: Mandaviya

The government was working hard to enhance the production of antiviral drug Remdesivir to 300,000 vials per day, the minister said

Cadila Healthcare's Hepatitis C drug gets approval for emergency use

Approval from the drug regulator follows late-stage study of the medicine

Govt drops import duty on remdesivir ingredient, injections for Covid-19

Remdesivir is being used to treat Covid-19 patients, jacking up its demand.

World's largest vaccine maker India tees up global blitz to contain virus

India manufactures more than 60% of all vaccines sold across the globe

Practo's telemedicine subscription plans record 250% growth in 6 months

Most of the health plan users are from metro cities like Delhi, Bengaluru, and Mumbai

Juggat Pharma to set up 2 plants in FY22 to boost nutraceutical production

Its flagship product Mulmina, an antioxidant-rich immune boosting drink, has seen traction of over 150 per cent since April.

Lupin: Q2 unimpressive, more triggers required to drive stock

US growth has picked up as anticipated, but India and a few other markets still lag

With US sales recovering, Lupin Q2 profit up 97% over Q1 to Rs 211 cr

The revenues, however, dropped by 1.2 percent on a year on year (YoY) basis to Rs 3,835 crore, but sequentially the revenues rose 8.7 percent

We have an opportunity to replace China as global AC exporter: Blue Star MD

Blue Star's Managing Director B Thiagarajan spoke to T E Narasimhan on how sales are expected to touch pre-Covid-19 levels during festival time and there are chances it may increase by 10 per cent

Nigerian regulator blacklists Vadodara firm over substandard drugs

Matter relates to eight batches of drug made by Mars Remedies from for a Nigerian pharma company; all its products are now barred from entry into African nation

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up

Higher sales in domestic market, lower costs bode well for Glenmark

The other trigger for the stock is the cost savings from lower investments in R&D and fund raising for innovation research

Kochi firm gets nod to test India's first novel molecule for Covid-19

PNB Vesper's drug developed from 12 years of research for small-cell lung cancer (for which it is under trial) has shown positive response in Covid-19, the firm claims

AstraZeneca Pharma India Q1 net profit declines 13 pc at Rs 18.63 cr

Drug firm AstraZeneca Pharma India on Monday reported a 13.38 per centdecline in its net profit to Rs 18.63 crore for the quarter ended June. The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing. Revenue from operations stood at Rs 193.57 crore for the quarter under consideration. It was Rs 204.56 crore for the same periodyear ago, it added. The board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2020-21, the filing said. Shares ofAstraZeneca Pharma India were trading at Rs3,381.65per scrip on BSE, up 1.50 per cent over previous close.